Pretreatment Controlling Nutritional Status Score and Lactate Dehydrogenase as Predictive Markers of Survival in Patients with Malignant Peritoneal Mesothelioma

References

• Munkholm-Larsen S, Cao CQ, and Yan TD: Malignant peritoneal mesothelioma. World J Gastrointest Surg 1, 38–48, 2009.
   PubMedGoogle Scholar
• Alastair JM, Robert JP, and John W: Malignant mesothelioma. Orphanet J Rare Dis 3, 1750–1172, 2008.
   Web of Science ®Google Scholar
• Kindler HL: Peritoneal mesothelioma: the site of origin matters. Am Soc Clin Oncol Educ Book 33, 182–188, 2013.
   Google Scholar
• Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353,1591–1603, 2005.
   PubMed Web of Science ®Google Scholar
• Kattan J, Eid R, Kourie HR, Farhat F, Ghosn M, et al.: Mesotheliomas in Lebanon: witnessing a change in epidemiology. Asian Pac J Cancer Prev 17, 4169–4173, 2016.
   PubMedGoogle Scholar
• Xinyi S, Guoqi Z, Chendi L, Guozun Z, Derui Y, et al.: Ultrasound imaging analysis of diffuse malignant peritoneal mesothelioma. Clin Focus 32, 323–325, 2017.
   Google Scholar
• Si Chen W, Guo Qi Z, and Zhi G: Wang: Retrospective analysis of clinical data of 162 cases of peritoneal malignant mesothelioma in Cangzhou. Chin J Intern Med 52, 599–601, 2013.
   Google Scholar
• Tokunaga R, Sakamoto Y, Nakagawa S, Ohuchi M, Izumi D, et al.: CONUT: A novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. Int J Colorectal Dis 32, 99–106, 2017.
   PubMed Web of Science ®Google Scholar
• Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, et al.: Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. Urol Oncol 35, 539.e9–539.e16, 2017.
   Web of Science ®Google Scholar
• Akamine T, Toyokawa G, and Matsubara T: Significance of the preoperative CONUT score in predicting postoperative disease-free and overall survival in patients with lung adenocarcinoma with obstructive lung disease. Anticancer Res 37, 2735–2742, 2017.
   PubMed Web of Science ®Google Scholar
• Takagi K, Yagi T, Umeda Y, Shinoura S, Yoshida R, et al.: Preoperative controlling nutritional status (CONUT) score for assessment of prognosis following hepatectomy for hepatocellular carcinoma. World J Surg 41, 2353–2360, 2017.
   PubMed Web of Science ®Google Scholar
• Schütte K, Tippelt B, Schulz C, Röhl FW, Feneberg A, et al.: Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr 34, 1122–1127, 2015.
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, Zamboli A, De Vita F, Castellano P, et al.: Neutrophil to lymphocyte ratio is a strong predictor of tumor recurrence in early colon cancers: a propensity score-matched analysis. Surgery 158, 112–120, 2015.
   PubMed Web of Science ®Google Scholar
• Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, et al.: Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 88,890–894, 2013.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, George DJ, and Halabi S: Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 30, 3402–3407, 2012.
   PubMed Web of Science ®Google Scholar
• Wulaningsih W, Holmberg L, Garmo H, Malmstrom H, Lambe M, et al.: Serum lactate dehydrogenase and survival following cancer diagnosis. Br J Cancer 113, 1389–1396, 2015.
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, et al.: Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137, 647–667, 2013.
   PubMed Web of Science ®Google Scholar
• Miller J and Wynn H: A malignant tumor arising from the endothelium of the peritoneum and producing a mucoid ascitic fluid. J Pathol Bacteriol 12,267, 1908.
   Google Scholar
• Sharma H, Bell I, Schofield J, and Bird G: Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepathol Gastroenterol 35, 55–59, 2011.
   PubMed Web of Science ®Google Scholar
• Sneddon S, Patch A-M, Dick IM, Kazakoff S, Pearson JV, et al.: Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer 17, 396, 2017.
   PubMed Web of Science ®Google Scholar
• Haber SE and Haber JM: Malignant mesothelioma: A clinical study of 238 cases. Ind Health 49,166–172, 2011.
   PubMed Web of Science ®Google Scholar
• Shavelle R, Vavra-Musser K, Lee J, and Brooks J: Life expectancy in pleural and peritoneal mesothelioma. Lung Cancer Int 2017, 2782590, 2017.
   PubMedGoogle Scholar
• Liang Y-F, Zheng G-Q, Chen Y-F, Song H, Yin W-J, et al.: CT differentiation of diffuse malignant peritoneal mesothelioma and peritoneal carcinomatosis. J Gastroenterol Hepatol 31, 709–715, 2016.
   PubMed Web of Science ®Google Scholar
• Yin W-J, Zheng G-Q, Chen Y-F, Chen D-Q, Sun N-N, et al.: CT differentiation of malignant peritoneal mesothelioma and tuberculous peritonitis. Radiol Med 121, 253–260, 2016.
   PubMed Web of Science ®Google Scholar
• Schonfeld SJ, McCormack V, Rutherford MJ, and Schüz J: Regional variations in German mesothelioma mortality rates: 2000–2010. Cancer Causes Control 25, 615–624, 2014.
   PubMed Web of Science ®Google Scholar
• Fujimoto E, Kijima T, Kuribayashi K, Negi Y, Kanemura S, et al.: First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther 17, 865–872, 2017.
   PubMed Web of Science ®Google Scholar
• Shi Y and Pinto BM: Human lactate dehydrogenase a inhibitors: a molecular dynamics investigation. PLoS One 9,e86365, 2014.
   PubMed Web of Science ®Google Scholar
• Faloppi L, Bianconi M, Giampieri R, Sobrero A, and Labianca R: The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget 6, 35087–35094, 2015.
   PubMedGoogle Scholar
• Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, et al.: Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 30, 607–613, 2012.
   PubMed Web of Science ®Google Scholar
• Takamori S, Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, et al.: The controlling nutritional status score is a significant independent predictor of poor prognosis in patients with malignant pleural mesothelioma. Clin Lung Cancer 18,303–313, 2017.
   PubMed Web of Science ®Google Scholar
• Takahiro T, Naoshi K, Tatsuro T, Katsunobu S, Ryosuke A, et al.: The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: Results from retrospective study. BMC Cancer 16, 722, 2016.
   PubMed Web of Science ®Google Scholar
• Iseki Y, Shibutani M, Maeda K, Nagahara H, Ohtani H, et al.: Impact of the Preoperative Controlling Nutritional Status (CONUT) score on the survival after curative surgery for colorectal cancer. PLoS One 10,e0132488, 2015.
   PubMed Web of Science ®Google Scholar
• Iwakami N, Nagai T, Furukawa TA, Sugano Y, Honda S, et al.: Prognostic value of malnutrition assessed by Controlling Nutritional Status score for long-term mortality in patients with acute heart failure. Int J Cardiol 230,529–536, 2017.
   PubMed Web of Science ®Google Scholar